{"id":"bnt162b7-bivalent-original-omi-ba-4-ba-5","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Cobicistat","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Rilpivirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Amprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Cobicistat","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Rilpivirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Amprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Cobicistat","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Rilpivirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Amprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Cobicistat","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Rilpivirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir alafenamide","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tenofovir disoproxil fumarate","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Amprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Cobicistat","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased antiviral activity"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased antiviral activity"}],"commonSideEffects":[{"effect":"Injection site pain (PAIN)","drugRate":"82.7%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":86,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"73.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":76,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"52.9%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":55,"trialsReporting":1},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"35.6%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":37,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"21.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":22,"trialsReporting":1},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"18.3%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":19,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"14.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":15,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"10.6%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":11,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"5.8%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":6,"trialsReporting":1},{"effect":"COVID-19","drugRate":"2.9%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":3,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"1.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":2,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"1.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":1,"trialsReporting":1},{"effect":"Back pain","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Bell's palsy","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Ear pain","drugRate":"0.0%","organSystem":"Ear and labyrinth disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Fatigue","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Headache","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Hypercholesterolaemia","drugRate":"0.0%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site pain","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Joint abscess","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Lymphadenopathy","drugRate":"0.0%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Myalgia","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Otitis media","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Thermal burn","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vomiting","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal mycotic infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal pruritus","drugRate":"0.0%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1}],"contraindications":["Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.","Events of anaphylaxis have been reported.","Subsequent dose(s) of the vaccine should not be given to those who have experienced anaphylaxis to the earlier dose of COMIRNATY.","Myocarditis and pericarditis","Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection.","Thrombocytopenia and coagulation disorders","Immunocompromised individuals"],"specialPopulations":{"Pregnancy":"Pregnant and lactating people are strongly encouraged to get vaccinated to provide protection to infants too young to vaccinate. Growing evidence supports vaccination during pregnancy to improve maternal, fetal and neonatal outcomes.","Geriatric use":"Adults ages 65 and older who are not immunocompromised may receive an additional booster dose at least 4 months after their first dose of bivalent mRNA vaccine.","Paediatric use":"Primary dosing schedules for children ages 6 months through 5 years are more complex because mRNA products come in different dose strengths and the required number of doses differs based on age. All children should receive at least one dose of bivalent vaccine, but the number of doses needed varies depending on what vaccine the child has previously received. It is ideal for infants and young children to receive all doses in their primary vaccine series from the same vaccine product. The primary dosing schedule for children ages 6 through 11 years more closely aligns with the schedule for adolescents and adults. A single bivalent primary dose or one bivalent booster dose at least 8 weeks after the last monovalent dose is recommended.","Renal impairment":"text","Immunocompromised":"People who are moderately or severely immunocompromised are at higher risk for severe COVID-19 infection than the general population. They may need additional doses in their primary vaccine series, as well as additional booster doses. Bivalent mRNA vaccines are preferred unless contraindicated. Patients who are moderately or severely immunocompromised can self-attest and be vaccinated against COVID-19 without needing to provide documentation.","Hepatic impairment":"text"},"seriousAdverseEvents":[{"event":"Acute kidney injury","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Gastroenteritis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Normocytic anaemia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Adenocarcinoma pancreas","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Alcohol poisoning","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Arrhythmia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Back pain","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Biliary colic","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Diverticulitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Enterocolitis infectious","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypoglycaemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypokalaemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypotension","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Left ventricular failure","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Leukaemia","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pancreatitis acute","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Post procedural infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Prostate cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Small intestinal obstruction","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Suicidal ideation","detail":"Psychiatric disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Syncope","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Testicular germ cell cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Type 2 diabetes mellitus","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Urinary tract obstruction","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:55:00.671846+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:55:10.877001+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5791340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:54:54.311082+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:55:12.354334+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:54:52.732419+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:55:12.354325+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:55:32.586612+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:36:29.512580+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:55:32.586542+00:00"}},"allNames":"bnt162b7 bivalent (original/omi ba.4/ba.5)","offLabel":[],"timeline":[],"aiSummary":"BNT162b7 Bivalent (Original/OMI BA.4/BA.5) by Pfizer holds a significant market position as a leading mRNA-based vaccine, though it has not been the world's best-selling drug. The vaccine's competitive advantage lies in its bivalent formulation, which targets both the original SARS-CoV-2 strain and the Omicron BA.4/BA.5 subvariants, offering broader protection compared to monovalent vaccines. However, a key risk is the presence of strong competition from Moderna’s mRNA-1273.222, which has demonstrated greater efficacy in preventing COVID-19-related hospitalizations and outpatient encounters. Looking ahead, the pipeline for BNT162b7 Bivalent does not include any ongoing clinical trials, suggesting a focus on current market penetration and potential future adaptations to emerging variants.","brandName":"BNT162b7 Bivalent (Original/OMI BA.4/BA.5)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein","novelty":"best-in-class","modality":"mRNA","drugClass":"mRNA vaccine","explanation":"BNT162b7 Bivalent is a type of mRNA vaccine, which uses a piece of genetic material called messenger RNA to instruct cells in the body to produce a specific protein. In this case, the protein is the SARS-CoV-2 spike protein, which is found on the surface of the COVID-19 virus. The vaccine works by stimulating the body's immune system to produce antibodies and immune cells that can recognize and fight the virus. This provides protection against COVID-19 infection.","oneSentence":"BNT162b7 Bivalent is a mRNA-based vaccine targeting SARS-CoV-2 spike protein.","technicalDetail":"BNT162b7 Bivalent uses a lipid nanoparticle formulation to deliver the mRNA to cells, where it is translated into the spike protein. The immune system then recognizes the protein as foreign and mounts an immune response against it. This response includes the production of antibodies and immune cells that can recognize and bind to the spike protein, providing protection against COVID-19 infection."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL5791340","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":null,"withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":"$21.2B"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bnt162b7-bivalent-original-omi-ba-4-ba-5","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b7-bivalent-original-omi-ba-4-ba-5","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:36:36.405280+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"mRNA-1273.222","company":"Moderna","advantage":"More effective than BNT162b2 Bivalent in preventing COVID-19-related hospitalizations and outpatient encounters"},{"name":"BNT162b2","company":"Pfizer BioNTech","advantage":"Used a similar vaccine technology, but less effective than mRNA-1273.222 in preventing COVID-19-related hospitalizations and outpatient encounters"}],"genericName":"bnt162b7-bivalent-original-omi-ba-4-ba-5","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"","acronym":null,"sponsor":"BioNTech SE","isPivotal":false,"primaryCI":"","primaryHR":"","enrollment":1453,"indication":"SARS-CoV-2 Infection, COVID-19","endpointCount":40,"primaryPValue":"","completionDate":"","primaryEndpoint":"Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination"}],"_emaApprovals":[{"date":"","name":"BNT162b7 Bivalent (Original/OMI BA.4/BA.5)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5791340"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[{"nctId":"NCT05472038","groups":[{"id":"FG000","title":"Cohort 1: 18-55 Years (BNT162b5 Bivalent [WT/ OMI BA.2] 30 mcg)","description":"Participants aged 18-55 years received BNT162b5 Bivalent (wild type \\[WT\\]/ omicron \\[OMI\\] BA.2) 30 micrograms (mcg) intramuscularly at Visit 1 (Day 1)."},{"id":"FG001","title":"Cohort 1: 18-55 Years (BNT162b2 Bivalent [WT/ OMI BA.1] 30 mcg)","description":"Participants aged 18-55 years received BNT162b2 Bivalent (WT/ OMI BA.1) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG002","title":"Cohort 2 (Group 1): 12-17 Years (BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 30 mcg)","description":"Participants aged 12-17 years received BNT162b2 Bivalent (WT/ OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG003","title":"Cohort 2 (Group 2) + Cohort 3 (Group 1): 18-55 Years (BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 30 mcg)","description":"Participants aged 18-55 years received BNT162b2 Bivalent (WT/ OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG004","title":"Cohort 2 (Group 3): 18-55 Years (BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 60 mcg)","description":"Participants aged 18-55 years received BNT162b2 Bivalent (WT/ OMI BA.4/ BA.5) 60 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG005","title":"Cohort 2 (Group 4) + Cohort 3 (Group 2): >55 Years (BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 30 mcg)","description":"Participants aged more than (\\>) 55 years received BNT162b2 Bivalent (WT/ OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG006","title":"Cohort 2 (Group 5): >55 Years (BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 60 mcg)","description":"Participants aged \\>55 years received BNT162b2 Bivalent (WT/ OMI BA.4/ BA.5) 60 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG007","title":"Cohort 4: 18-55 Years (BNT162b2 Bivalent [Original/ OMI BA.4 /BA.5] 30 mcg)","description":"Participants aged 18-55 years received BNT162b2 Bivalent (Original/ OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG008","title":"Cohort 4: 18-55 Years (BNT162b5 Bivalent [Original/ OMI BA.4/ BA.5] 30 mcg)","description":"Participants aged 18-55 years received BNT162b5 Bivalent (Original/ OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG009","title":"Cohort 4: 18-55 Years (BNT162b6 Bivalent [Original/ OMI BA.4/ BA.5] 30 mcg)","description":"Participants aged 18-55 years received BNT162b6 Bivalent (Original/ OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG010","title":"Cohort 4: 18-55 Years (BNT162b7 Bivalent [Original/ OMI BA.4/ BA.5] 30 mcg)","description":"Participants aged 18-55 years received BNT162b7 Bivalent (Original/ OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."},{"id":"FG011","title":"Cohort 4: 18-55 Years (BNT162b7 Monovalent [OMI BA.4/ BA.5] 30 mcg)","description":"Participants aged 18-55 years received BNT162b7 Monovalent (OMI BA.4/ BA.5) 30 mcg intramuscularly at Visit 1 (Day 1)."}],"acronym":null,"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","counts":{"FG000":"104","FG001":"102","FG002":"108","FG003":"314","FG004":"110","FG005":"306","FG006":"102","FG007":"62","FG008":"62","FG009":"60","FG010":"60","FG011":"63"}},{"type":"COMPLETED","counts":{"FG000":"102","FG001":"96","FG002":"103","FG003":"298","FG004":"106","FG005":"300","FG006":"101","FG007":"59","FG008":"57","FG009":"58","FG010":"55","FG011":"59"}},{"type":"NOT COMPLETED","counts":{"FG000":"2","FG001":"6","FG002":"5","FG003":"16","FG004":"4","FG005":"6","FG006":"1","FG007":"3","FG008":"5","FG009":"2","FG010":"5","FG011":"4"}}],"dropWithdraws":[{"type":"Adverse Event","counts":{"FG000":"0","FG001":"0","FG002":"1","FG003":"0","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0"}},{"type":"Death","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"1","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0"}},{"type":"Lost to Follow-up","counts":{"FG000":"1","FG001":"3","FG002":"3","FG003":"9","FG004":"2","FG005":"2","FG006":"1","FG007":"0","FG008":"1","FG009":"0","FG010":"2","FG011":"1"}},{"type":"Physician Decision","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"1","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0"}},{"type":"Withdrawal by Subject","counts":{"FG000":"1","FG001":"3","FG002":"1","FG003":"6","FG004":"1","FG005":"3","FG006":"0","FG007":"2","FG008":"3","FG009":"1","FG010":"2","FG011":"2"}},{"type":"Protocol Violation","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"0","FG006":"0","FG007":"1","FG008":"1","FG009":"1","FG010":"1","FG011":"1"}},{"type":"Not vaccinated","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"1","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0"}}]}],"recruitment":"The study consisted of 4 cohorts. Cohort 1 and 4 had distinct participant groups and objectives. Where appropriate, and as per planned analyses, data is summarized and combined for Cohort 2 (C2) and Cohort 3 (C3) 30 micrograms (mcg) groups (G) per age category to provide sufficient power for the immunogenicity hypotheses for each of the age groups.","preAssignment":"Study consisted of 4 cohorts. Cohort 1 and 4 had distinct participant groups and objectives, while cohorts are different, they are part of same study. Both arms (Cohort 2 Group 2 and Cohort 3 Group 1) and (Cohort 2 Group 4 and Cohort 3 Group 2) received the same treatment and are from the same age group. As mentioned in the Protocol Objective section, arms with the same treatment and age group will be combined to provide a more comprehensive summary, rather than being listed in separate columns."}],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"2.91","nctId":"NCT05472038","phase":"PHASE2, PHASE3","pValue":"","ciLower":"2.45","ciUpper":"3.44","endpoint":"GMR of Omicron (BA.4/BA.5)- NT of BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 30 mcg Cohort 2 (Group 4)/ Cohort 3 (Group 2) Combined in C4591044 Compared to NT of BNT162b2 30 mcg in C4591031 [NCT04955626]- 1 Month After Vaccination Among Participants >55 Years","enrollment":1453}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"mRNA","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:36:36.405280+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}